Corrigendum to "The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2021;100:225-237

Affiliations

• ¹ Paediatric Nephrology Department, University Hospital Vall d'Hebron, Barcelona, Spain. Electronic address: gariceta@vhebron.net.
• ² Renal Section, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.
• ³ Department of Pediatrics, Pusan National University Children's Hospital, Yangsan, Korea.
• ⁴ Faculty of Pediatric Sciences, Central Michigan University, Mount Pleasant, Michigan, USA.
• ⁵ Division of Pediatric Nephrology, University of Nebraska Medical Center, Omaha Children's Hospital and Medical Center, Omaha, Nebraska, USA; Department of Nephrology and Hypertension, Division of Pediatrics, University of Utah, Salt Lake City, Utah, USA.
• ⁶ Clinical and Non-Clinical Pharmacology, Alexion Pharmaceuticals Inc., Boston, Massachusetts, USA.
• ⁷ Biostatistics, Alexion Pharmaceuticals Inc., Boston, Massachusetts, USA.
• ⁸ Clinical Development, Alexion Pharmaceuticals Inc., Boston, Massachusetts, USA.
• ⁹ Division of Pediatric Nephrology, Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.
• ¹⁰ Division of Pediatric Nephrology, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.